Lyon (France), August 31, 2017 - Valneva SE ("Valneva" or "the Company"), a fully integrated, commercial stage biotech company focused on developing innovative, life-saving vaccines, reported today its consolidated financial results for the first half ended June 30, 2017.

  • Total revenues and grants of €55.4 million in H1 2017 (with total product sales growth of 17.5% compared to H1 2016)
  • EBITDA increased strongly in H1 2017 reaching €7.6 million (vs. €4.7 million in H1 2016)
  • Net loss was significantly reduced in H1 2017 to €4.4 million compared to a net loss of €39.5 million in H1 2016
  • Positive operating cash flow amounted to €16.6 million in H1 2017 (vs. €3.9 million in H1 2016) bringing Valneva's cash position to €47.3 million at the end of June 2017

A webcast for financial analysts, fund managers, investors and journalists will be held today at 2:00 pm (CET). A replay will be available on the Company's website. Please refer to this link: Webcast

Valneva SE published this content on 31 August 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 31 August 2017 08:07:08 UTC.

Original documenthttp://www.valneva.com/en/investors-media/news

Public permalinkhttp://www.publicnow.com/view/11E8371FA063E9BF1FCB66C0CE5AB818768D108B